Page last updated: 2024-08-23

amonafide and Cancer of Liver

amonafide has been researched along with Cancer of Liver in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (66.67)24.3611
2020's1 (33.33)2.80

Authors

AuthorsStudies
Chen, Y; Jia, H; Li, L; Li, Y; Ma, J; Ma, R; Ma, Y; Su, S; Wang, C; Wang, J; Xie, S; Yu, L; Yue, K; Zhang, P; Zhang, Z1
Chen, J; Kim, DH; Larson, AC; Omary, RA1
Li, Q; Li, Z; Wang, CJ; Xie, SQ; Zhang, YH; Zhao, J1

Other Studies

3 other study(ies) available for amonafide and Cancer of Liver

ArticleYear
A naphthalimide-polyamine conjugate preferentially accumulates in hepatic carcinoma metastases as a lysosome-targeted antimetastatic agent.
    European journal of medicinal chemistry, 2021, Oct-05, Volume: 221

    Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Liver Neoplasms; Lysosomes; Molecular Structure; Naphthalimides; Polyamines; Structure-Activity Relationship

2021
MRI visible drug eluting magnetic microspheres for transcatheter intra-arterial delivery to liver tumors.
    Theranostics, 2015, Volume: 5, Issue:5

    Topics: Adenine; Alginates; Animals; Antineoplastic Agents; Disease Models, Animal; Drug Carriers; Glucuronic Acid; Hexuronic Acids; Injections, Intra-Arterial; Liver Neoplasms; Magnetic Resonance Imaging; Microspheres; Naphthalimides; Organophosphonates; Rats

2015
BND-12, a novel nonhaematotoxic naphthalimide derivative, inhibits tumour growth and metastasis of hepatocellular carcinoma.
    The Journal of pharmacy and pharmacology, 2012, Volume: 64, Issue:10

    Topics: Adenine; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Humans; Liver Neoplasms; Male; Mice; Mitochondria; Naphthalimides; Neoplasm Metastasis; Organophosphonates; Survival Rate; Toxicity Tests; Xenograft Model Antitumor Assays

2012